Study participants are randomized to receive either the Reveal LINQ implantable cardiac monitor (inserted within 10 days of the qualifying stroke) or the usual standard of care for ischemic stroke. This study requires participants to return for follow-up clinic visits at 1 month (post hospital discharge) then every 3 months for 1 year. After 1 year, follow-up is required every 6 months for approximately 3 years.
- Trial ID:
- Mary Kalafut, M.D.
- Have had an ischemic stroke of presumed known origin within 10 days of study enrollment
- Be willing and able to undergo all study requirements and complete the study required follow-up
- Be 60 years of age or older, or age 50 to 59 with a documented medical history of at least one additional risk factor for stroke
- Meet all other eligibility criteria
- Have had a stroke of unknown origin or had a cardioembolic stroke
- Have untreated hyperthyroidism
- Have had a recent heart attack or cardiac surgery
- Have a mechanical heart valve
- Have valvular disease requiring immediate surgical intervention.
- Have documented atrial fibrillation or atrial flutter.
- Have an indication for oral anticoagulation.
- Be enrolled in a another clinical trial
- American Heart Association guidelines recommend cardiac monitoring with a Holter monitor for up to 30 days after a patient has a stroke to watch for signs of atrial fibrillation (a-fib). Previous research has suggested that monitoring for a longer period of time is better at detecting symptoms of a-fib in more patients.
- Insertable cardiac monitors like the Reveal LINQ Cardiac monitor continuous monitor heart rhythms and can detect infrequent episodes of a-fib for up to 3 years.